.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The BLISS-52 randomized trial provided pivotal evidence for belimumab, a monoclonal antibody targeting the B-lymphocyte stimulator pathway, in active systemic lupus erythematosus receiving standard therapy. Belimumab improved the proportion of patients achieving a defined composite response compared with placebo, supporting biologic therapy as an additional option for selected patients with active disease. For internists, the study is relevant because SLE often presents with multisystem symptoms and can be difficult to distinguish from infection, drug effects or other autoimmune conditions. Treatment decisions should therefore be phenotype-driven and balanced against organ involvement, disease severity and infection risk. Belimumab is not a replacement for urgent high-intensity immunosuppression when there is immediately organ-threatening disease. Instead, it can form part of longer-term disease control in appropriate patients. The broader lesson is that SLE management increasingly requires targeted therapy combined with careful monitoring and steroid-sparing strategies. A structured approach to vaccination, infection screening, reproductive planning and cardiovascular risk is essential because long-term outcomes depend on much more than lupus activity alone.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The BLISS-52 randomized trial provided pivotal evidence for belimumab, a monoclonal antibody targeting the B-lymphocyte stimulator pathway, in active systemic lupus erythematosus receiving standard therapy. Belimumab improved the proportion of patients achieving a defined composite response compared with placebo, supporting biologic therapy as an additional option for selected patients with active disease. For internists, the study is relevant because SLE often presents with multisystem symptoms and can be difficult to distinguish from infection, drug effects or other autoimmune conditions. Treatment decisions should therefore be phenotype-driven and balanced against organ involvement, disease severity and infection risk. Belimumab is not a replacement for urgent high-intensity immunosuppression when there is immediately organ-threatening disease. Instead, it can form part of longer-term disease control in appropriate patients. The broader lesson is that SLE management increasingly requires targeted therapy combined with careful monitoring and steroid-sparing strategies. A structured approach to vaccination, infection screening, reproductive planning and cardiovascular risk is essential because long-term outcomes depend on much more than lupus activity alone.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
